Annual SG&A
$13.54 M
-$8.00 M-37.14%
31 December 2023
Summary:
OncoCyte annual selling, general & administrative expenses is currently $13.54 million, with the most recent change of -$8.00 million (-37.14%) on 31 December 2023. During the last 3 years, it has fallen by -$6.86 million (-33.62%). OCX annual SG&A is now -41.86% below its all-time high of $23.28 million, reached on 31 December 2020.OCX Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly SG&A
$3.61 M
+$348.00 K+10.67%
30 September 2024
Summary:
OncoCyte quarterly selling, general & administrative expenses is currently $3.61 million, with the most recent change of +$348.00 thousand (+10.67%) on 30 September 2024. Over the past year, it has increased by +$1.22 million (+50.90%). OCX quarterly SG&A is now -57.18% below its all-time high of $8.43 million, reached on 30 September 2021.OCX Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM SG&A
-$1.21 B
-$44.56 M-3.83%
30 September 2024
Summary:
OncoCyte TTM selling, general & administrative expenses is currently -$1.21 billion, with the most recent change of -$44.56 million (-3.83%) on 30 September 2024. Over the past year, it has dropped by -$1.22 billion (-9035.02%). OCX TTM SG&A is now -7754.04% below its all-time high of $29.01 million, reached on 30 September 2021.OCX TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
OCX Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | +50.9% | -9035.0% |
| 3 y3 years | -33.6% | +212.5% | -5993.7% |
| 5 y5 years | -12.4% | -30.7% | -7930.6% |
OCX Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -37.1% | at low | -39.0% | +212.5% | -99.8% | at low |
| 5 y | 5 years | -41.9% | at low | -57.2% | +212.5% | -260.7% | at low |
| alltime | all time | -41.9% | +2352.2% | -57.2% | +212.5% | -7754.0% | at low |
OncoCyte Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $3.61 M(+10.7%) | $12.78 M(+3.4%) |
| June 2024 | - | $3.26 M(-7.4%) | $12.35 M(-4.6%) |
| Mar 2024 | - | $3.52 M(+47.2%) | $12.95 M(-4.3%) |
| Dec 2023 | $13.54 M(-37.1%) | $2.39 M(-24.9%) | $13.54 M(-14.2%) |
| Sept 2023 | - | $3.18 M(-17.4%) | $15.77 M(-13.0%) |
| June 2023 | - | $3.85 M(-6.1%) | $18.13 M(-8.1%) |
| Mar 2023 | - | $4.11 M(-11.2%) | $19.73 M(-8.4%) |
| Dec 2022 | $21.53 M(+5.6%) | $4.62 M(-16.7%) | $21.53 M(+57.1%) |
| Sept 2022 | - | $5.55 M(+1.9%) | $13.70 M(-17.4%) |
| June 2022 | - | $5.45 M(-7.9%) | $16.58 M(-14.6%) |
| Mar 2022 | - | $5.91 M(-284.4%) | $19.42 M(-5.4%) |
| Dec 2021 | $20.39 M(-12.4%) | -$3.21 M(-138.1%) | $20.52 M(-29.3%) |
| Sept 2021 | - | $8.43 M(+1.7%) | $29.01 M(+6.9%) |
| June 2021 | - | $8.28 M(+18.0%) | $27.15 M(+12.3%) |
| Mar 2021 | - | $7.02 M(+32.8%) | $24.19 M(+3.9%) |
| Dec 2020 | $23.28 M(+50.7%) | $5.28 M(-19.5%) | $23.28 M(+0.3%) |
| Sept 2020 | - | $6.56 M(+23.3%) | $23.20 M(+14.5%) |
| June 2020 | - | $5.32 M(-13.0%) | $20.27 M(+7.2%) |
| Mar 2020 | - | $6.12 M(+17.5%) | $18.91 M(+22.4%) |
| Dec 2019 | $15.45 M | $5.21 M(+43.3%) | $15.45 M(+18.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2019 | - | $3.63 M(-8.1%) | $13.08 M(+19.5%) |
| June 2019 | - | $3.95 M(+49.0%) | $10.95 M(+23.0%) |
| Mar 2019 | - | $2.65 M(-6.6%) | $8.90 M(+2.4%) |
| Dec 2018 | $8.69 M(-25.6%) | $2.84 M(+90.0%) | $8.69 M(+5.6%) |
| Sept 2018 | - | $1.50 M(-21.4%) | $8.23 M(-29.9%) |
| June 2018 | - | $1.90 M(-22.1%) | $11.73 M(+2.7%) |
| Mar 2018 | - | $2.44 M(+2.5%) | $11.42 M(-2.2%) |
| Dec 2017 | $11.68 M(+113.7%) | $2.38 M(-52.3%) | $11.67 M(+6.6%) |
| Sept 2017 | - | $5.00 M(+214.0%) | $10.95 M(+52.7%) |
| June 2017 | - | $1.59 M(-41.0%) | $7.17 M(+3.7%) |
| Mar 2017 | - | $2.70 M(+62.2%) | $6.92 M(+26.6%) |
| Dec 2016 | $5.46 M(+30.4%) | $1.66 M(+36.4%) | $5.46 M(-7.6%) |
| Sept 2016 | - | $1.22 M(-8.8%) | $5.91 M(-1.5%) |
| June 2016 | - | $1.34 M(+7.6%) | $6.00 M(+15.8%) |
| Mar 2016 | - | $1.24 M(-41.1%) | $5.18 M(+23.7%) |
| Dec 2015 | $4.19 M(+314.5%) | $2.11 M(+60.8%) | $4.19 M(+70.8%) |
| Sept 2015 | - | $1.31 M(+152.8%) | $2.45 M(+114.9%) |
| June 2015 | - | $519.00 K(+107.6%) | $1.14 M(+83.3%) |
| Mar 2015 | - | $250.00 K(-33.0%) | $623.00 K(+67.0%) |
| Dec 2014 | $1.01 M(+83.2%) | $373.00 K | $373.00 K |
| Dec 2013 | $552.00 K | - | - |
FAQ
- What is OncoCyte annual selling, general & administrative expenses?
- What is the all time high annual SG&A for OncoCyte?
- What is OncoCyte quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for OncoCyte?
- What is OncoCyte quarterly SG&A year-on-year change?
- What is OncoCyte TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for OncoCyte?
- What is OncoCyte TTM SG&A year-on-year change?
What is OncoCyte annual selling, general & administrative expenses?
The current annual SG&A of OCX is $13.54 M
What is the all time high annual SG&A for OncoCyte?
OncoCyte all-time high annual selling, general & administrative expenses is $23.28 M
What is OncoCyte quarterly selling, general & administrative expenses?
The current quarterly SG&A of OCX is $3.61 M
What is the all time high quarterly SG&A for OncoCyte?
OncoCyte all-time high quarterly selling, general & administrative expenses is $8.43 M
What is OncoCyte quarterly SG&A year-on-year change?
Over the past year, OCX quarterly selling, general & administrative expenses has changed by +$1.22 M (+50.90%)
What is OncoCyte TTM selling, general & administrative expenses?
The current TTM SG&A of OCX is -$1.21 B
What is the all time high TTM SG&A for OncoCyte?
OncoCyte all-time high TTM selling, general & administrative expenses is $29.01 M
What is OncoCyte TTM SG&A year-on-year change?
Over the past year, OCX TTM selling, general & administrative expenses has changed by -$1.22 B (-9035.02%)